Navigation Links
Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Adrian Schwarzer, MD, Ph.D. to its Scientific Advisory Committee
Date:12/23/2013

MILLBROOK, N.Y., Dec. 23, 2013 /PRNewswire/ -- Dr. Schwarzer is affiliated with Hannover Medical School in Hannover, Germany at the Institute of Experimental Hematology and resident in the Department of Hematology, Oncology and Stem Cell Transplantation. Dr. Schwarzer has an MD in Immunology and Ph.D. in Molecular Medicine/Biochemistry. He is currently engaged in investigating the role of cap dependent translation in acute lymphoblastic leukemias with a special focus on T-ALL.

We at Egenix are delighted to have Dr. Schwarzer aboard and feel confident that he will make significant contributions to the advancement of science and medicine.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com

 


'/>"/>
SOURCE Egenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. KaloBios Appoints Donald R. Joseph as Chief Legal Officer
2. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair
3. Imaging Contract-Research Pioneer, Donald P. Rosen, MD, Named CEO of ACR Image Metrix™
4. Gregory Frank Named President of Two Leading Immunology Biotech Companies; Pure Protein and Pure MHC
5. Cargill’s Dielectric Transformer Oil Made from Natural Esters Wins Presidential Green Chemistry Award
6. The Leukemia & Lymphoma Societys "A Tribute to Jackie" Photo Collection Part of Auction Commemorating the 50th Anniversary of President Kennedys Assassination
7. TrialNetworks Co-founder and Chairman Vivek Murthy, MD, MBA, Nominated by President Barack Obama as Surgeon General of the United States of America
8. ISPE Names Dr. Thomas Zimmer as Vice President of European Operations
9. Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
10. Sigma-Aldrich Corporation Delcares Quarterly Dividend Of $0.215 Per Share And Announces Election Of New Vice President And Treasurer
11. Gentris Corporation Partners with BioFortis, Announces New Vice President of Information Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):